share_log

BZAM Ltd. & 4C LABS Conclude Strategic Distribution Agreement for the UK Market

BZAM Ltd. & 4C LABS Conclude Strategic Distribution Agreement for the UK Market

BZAM Ltd. 和 4C LABS 簽訂了英國市場的戰略分銷協議
PR Newswire ·  2023/11/01 05:05

VANCOUVER, BC, TORONTO and LONDON, Oct. 31, 2023 /PRNewswire/ - BZAM Ltd. (the "Company" or "BZAM") (CSE: BZAM) (US-OTC: BZAMF), is pleased to announce that its subsidiary, The Green Organic Dutchman Ltd. (collectively the "Company") completed its first shipment of Canadian certified organic, EU GMP medical cannabis to the UK on October 25, 2023. The Company is shipping its first 150kg of TGOD's top strains to 4C LABS for onward distribution to 4C LABS pharmacy clients in the United Kingdom (UK).

溫哥華,卑詩省多倫多倫敦2023年10月31日/美通社/-BZAM Ltd.(The“公司“或”BZAM)(美國場外交易市場代碼:BZAMF)高興地宣佈,其子公司綠色有機荷蘭人有限公司(以下簡稱“公司”)於#年#月#日完成了第一批加拿大認證有機、歐盟GMP醫用大麻的裝運。2023年10月25日。該公司將把第一批150公斤的TGOD頂級菌株運往4C實驗室,然後再分發給4C實驗室的藥房客戶英國(英國)。

Pursuant to the agreement, signed on April 29, 2023, the Company will supply 4C LABS with approximately 600KG of flower annually for the next two years.

根據協定,簽署於2023年4月29日,該公司將在未來兩年每年向4C實驗室供應約600公斤鮮花。

4C LABS believes that there is strong demand for quality, organic Canadian cannabis products in the UK's burgeoning medical cannabis market. The team at 4C LABS expects the market to expand over the next five years, mirroring previously legalized medical markets elsewhere, and expects this new agreement will enable them to establish a dominant position in the UK medical cannabis market.

4C實驗室認為,英國蓬勃發展的醫用大麻市場對優質、有機的加拿大大麻產品有著強勁的需求。4C實驗室的團隊預計,未來五年市場將擴大,反映出之前在其他地方合法化的醫療市場,並預計這項新協定將使他們能夠在英國醫用大麻市場確立主導地位。

Matt Milich, BZAM's CEO, stated: "We are proud to see our international export strategy go live in the UK. Executing on our recent EU GMP Certification is a key priority and we are excited to be able to partner with local experts like 4C LABS."

馬特·米利奇我們很高興看到我們的國際出口戰略在英國實施。執行我們最近的歐盟GMP認證是一個關鍵的優先事項,我們很高興能夠與像4C實驗室這樣的當地專家合作。

Greg Dobbin, 4C LABS CEO, stated: "We are extremely pleased to be able to offer The Green Organic Dutchman products to our UK & International pharmacies & clinics. BZAM is a world class company which operates a truly innovative facility where Canada's best growers and unique genetics come together. From feeding certain plants maple syrup to creating community gardens at their grow facility, the BZAM team takes medical cannabis to the next level."

格雷格·多賓,4C Labs首席執行官表示:“我們非常高興能夠向我們的英國和國際藥房和診所提供綠色有機荷蘭人產品。BZAM是一家世界級公司,運營著真正創新的設施,加拿大的最好的種植者和獨特的基因結合在一起。從給某些植物餵食楓糖漿,到在他們的種植設施中建立社區花園,BZAM團隊將醫用大麻帶到了一個新的水準。

About BZAM Ltd.
關於BZAM有限公司

BZAM Ltd. (CSE: BZAM) (US‐OTC: BZAMF) is a leading Canadian cannabis producer with a focus on branded consumer goods, innovation, quality, consistency, integrity and transparency. The BZAM family includes core brands BZAM, TGOD, ness, Highly Dutch Organic, TABLE TOP, and partner brands Dunn Cannabis, FRESH and Wyld. BZAM operates facilities in BC, Alberta, Ontario and Quebec, as well as a retail store in Regina, Saskatchewan.

BZAM有限公司(CSE:BZAM)(美國場外交易代碼:BZAMF)是加拿大領先的大麻生產商,專注於品牌消費品、創新、質量、一致性、誠信和透明度。BZAM系列包括核心品牌BZAM、TGOD、Ness、高度荷蘭有機、桌面以及合作品牌Dunn Cannabis、Fresh和Wyld。BZAM在不列顛哥倫比亞省運營設施,艾伯塔省安大略省魁北克,以及一家零售店裡賈納,薩斯喀徹溫省

BZAM's common shares and certain warrants issued under the indentures dated June 12, 2020, October 23, 2020 and December 10, 2020 currently trade on the Canadian Securities Exchange (the "CSE") under the symbol "BZAM", "BZAM.WR", "BZAM.WA", and "BZAM.WB" respectively. BZAM's common shares trade in the U.S. on the OTCQX under the symbol "BZAMF". For more information on BZAM Ltd., please visit .

BZAM的普通股及根據日期為日期的契約發行的若干認股權證2020年6月12日2020年10月23日2020年12月10日目前在加拿大證券交易所(TheCSE“)分別以”BZAM“、”BZAM.WR“、”BZAM.WA“和”BZAM.WB“的代碼。BZAM的普通股在美國聯交所以”BZAMF“的代碼交易。有關BZAM有限公司的更多資訊,請訪問。

About 4C LABS Ltd.
關於4C實驗室有限公司。

4C LABS Ltd. is a privately held Canadian medical cannabis company focusing on providing pharmacies & clinics with world class medical cannabis products at an affordable price. 4C LABS has import and distribution licenses in the UK and a wide network of pharmacies in the UK & Channel Islands. 4C LABS carries a full product line of medical cannabis from a selected network of trusted international cultivation partners. For more information, please visit

4C實驗室有限公司是一傢俬人持股的加拿大醫用大麻公司,專注於以實惠的價格向藥店和診所提供世界級的醫用大麻產品。4C實驗室在英國擁有進口和分銷許可證,在英國和海峽群島擁有廣泛的藥店網路。4C實驗室從選定的值得信賴的國際種植合作夥伴網路中攜帶了完整的醫用大麻生產線。欲瞭解更多資訊,請訪問

Cautionary Statements
警示聲明

This news release includes statements containing certain "forward–looking information" within the meaning of applicable securities law ("forward–looking statements"). Forward looking statements in this release include, but are not limited to, statements about future production quantity and timing, statements about the offering of any particular products by the Company and statements regarding the future performance of the Company, statements about funding availability, statements about growth and delivery of products, and statements about the level of demand for BZAM's products, statements relating to the creation and timing of any revenue in the UK, and statements about the future size of any international markets. Forward–looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "should", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward–looking statements throughout this news release, such as assumptions that the Company's financial trajectory will continue, the Company not having any issues with regulators, cultivation patterns at the Company's facilities continuing and there not being significant disruptions in cultivation such as disease or shortages in resources, the Company being insulated from supply chain issues and inflation affecting the global economy, the Company being able to access the capital markets and existing lenders for necessary funding, when necessary, demand for the Company's products continuing as expected and based on past trends. Forward–looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties (including market conditions) and other factors that could cause actual events or results to differ materially from those projected in the forward–looking statements, including those risk factors described in Management's Discussion and Analysis and the Company's most recent Annual Information Form filed with Canadian securities regulators and available on the Company's issuer profile on SEDAR at . Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

本新聞稿包括含有適用證券法所指的某些“前瞻性資訊”的陳述(“前瞻性陳述”)。本新聞稿中的前瞻性陳述包括但不限於關於未來生產數量和時間的陳述、關於公司提供任何特定產品的陳述和關於公司未來業績的陳述、關於資金可獲得性的陳述、關於產品增長和交付的陳述、關於對BZAM產品的需求水準的陳述、關於在英國創造任何收入的陳述以及關於任何國際市場未來規模的陳述。前瞻性表述經常使用諸如“計劃”、“繼續”、“預期”、“專案”、“打算”、“應該”、“相信”、“預期”、“估計”、“可能”、“將”、“可能”、“建議”等辭彙,或者某些事件或條件“可能”或“將”發生的表述。這些聲明只是預測。整個新聞稿中的前瞻性陳述中都使用了各種假設來得出結論或做出預測,例如假設公司的財務軌跡將繼續,公司與監管機構沒有任何問題,公司設施的種植模式仍在繼續,種植沒有重大中斷,如疾病或資源短缺,公司不受供應鏈問題和影響全球經濟的通脹的影響,公司能夠在必要時從資本市場和現有貸款人獲得必要的資金,對公司產品的需求按照預期並基於過去的趨勢繼續。前瞻性陳述以發表陳述之日管理層的意見和估計為基礎,受各種風險和不確定性(包括市場狀況)和其他因素的影響,這些因素可能會導致實際事件或結果與前瞻性陳述中預測的大不相同,包括管理層討論和分析以及公司提交給加拿大證券監管機構的最新年度資訊表格中描述的風險因素,並可在公司在SEDAR上的發行人簡介中查閱。。儘管本公司認為在準備本新聞稿中的前瞻性資訊或前瞻性陳述時使用的假設和因素是合理的,但不應過度依賴這些資訊,也不能保證此類事件將在披露的時間框架內發生或根本不會發生。本新聞稿中包含的前瞻性資訊和前瞻性陳述是截至本新聞稿發佈之日作出的。除適用法律明確要求外,公司沒有義務更新或修改任何前瞻性陳述,無論是由於新資訊、未來事件或其他原因,也明確表示不打算或承擔任何義務。

Neither the CSE nor the CSE's Regulation Services Provider (as that term is defined in the policies of CSE) accept responsibility for the adequacy or accuracy of this release.

CSE或CSE的監管服務提供商(該術語在CSE的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

SOURCE BZAM LTD.

來源:BZAM Ltd.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論